Glucose-Cholesterol Interaction Magnifies Coronary Heart Disease Risk for Hypertensive Patients

Abstract—Elevated cholesterol and glucose are known independent risk factors for coronary heart disease. This study examines whether an adverse synergistic interaction of cholesterol and glucose magnifies coronary heart disease risk among treated hypertensive patients. Subjects were hypertensive patients (n=6672) in a worksite treatment program, with entry fasting glucose <6.99 mmol/L (126 mg/dL) and total cholesterol <6.72 mmol/L (260 mg/dL) observed for mean 5.6±4.5 years follow-up (range 0.5 to 21.7 years). Outcome events were incident hospitalization or death due to coronary heart disease. Cox proportional hazard models were constructed for the whole sample to assess interaction and then stratified by fasting glucose categories with thresholds defined either at impaired fasting glucose (≥6.11 mmol/L [110 mg/dL]) or upper quartile (≥5.72 mmol/L [103 mg/dL]). An interaction product term of total cholesterol and fasting glucose as continuous variables significantly (P =0.009) improved a Cox proportional hazards model, adjusting for total cholesterol, fasting glucose, and other coronary heart disease risk factors. Adjusted hazard ratios for 3 upper total cholesterol categories (with total cholesterol <5.17mmol/L [200 mg/dL] as reference) in the higher fasting glucose stratum were more than double the corresponding hazard ratios in the lower stratum, whether using impaired fasting glucose or upper quartile fasting glucose as the cut point. These results suggest that an adverse synergistic interaction between glucose and cholesterol magnifies coronary heart disease risk associated with total cholesterol among hypertensive patients, raising the possibility that coronary heart disease prevention might be enhanced if cholesterol intervention criteria were modified by glucose status.

[1]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[2]  Sarah Parish,et al.  MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[3]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[4]  Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking. A preliminary report from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. , 1990, JAMA.

[5]  P. Hopkins,et al.  A survey of 246 suggested coronary risk factors. , 1981, Atherosclerosis.

[6]  H. Cohen,et al.  Glucose interaction magnifies atherosclerotic risk from cholesterol. Findings from the PDAY Study. , 2004, Atherosclerosis.

[7]  M. Alderman,et al.  Diabetes and cardiovascular events in hypertensive patients. , 1999, Hypertension.

[8]  D. Reed,et al.  Lipids and lipoproteins as predictors of coronary heart disease, stroke, and cancer in the Honolulu Heart Program. , 1986, The American journal of medicine.

[9]  M. Alderman,et al.  Detection and treatment of hypertension at the work site. , 1975, The New England journal of medicine.

[10]  Rupert G. Miller,et al.  Survival Analysis , 2022, The SAGE Encyclopedia of Research Design.

[11]  AndrewJ. S. Coats MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[12]  J. Neaton,et al.  Hypertension management in the Multiple Risk Factor Intervention Trial (MRFIT). Six-year intervention results for men in special intervention and usual care groups. , 1985, Archives of internal medicine.

[13]  M. Pagano,et al.  Survival analysis. , 1996, Nutrition.

[14]  M. Alderman,et al.  History of Treatment for Depression: Risk Factor for Myocardial Infarction in Hypertensive Patients , 2001, Psychosomatic medicine.

[15]  The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V) , 1993, Archives of internal medicine.

[16]  S Greenland,et al.  Concepts of interaction. , 1980, American journal of epidemiology.

[17]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[18]  S. Soegondo Atherogenic dyslipidemia and the metabolic syndrome. , 2005, Acta medica Indonesiana.

[19]  C. Puglia,et al.  Evaluation of oxidative stress in diabetic patients after supplementation with a standardised red orange extract. , 2002, Diabetes, nutrition & metabolism.

[20]  W. Kannel,et al.  A general cardiovascular risk profile: the Framingham Study. , 1976, The American journal of cardiology.

[21]  G. Renier,et al.  Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose : role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[22]  G. Sobal,et al.  Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.

[23]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[24]  Tomás Pantoja,et al.  Análisis crítico de un artículo Las estatinas reducen la morbi-mortalidad en pacientes de alto riesgo cardiovascular: Heart Protection Study Collaborative Group. (HPS). Lancet 2002; 360: 7-22. , 2003 .

[25]  Paul M. Ridker,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003 .

[26]  W. L. Ooi,et al.  Treatment-induced blood pressure reduction and the risk of myocardial infarction. , 1989, JAMA.

[27]  M. Alderman,et al.  High and low serum potassium associated with cardiovascular events in diuretic-treated patients , 2001, Journal of hypertension.

[28]  S. Grundy Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. , 1998, The American journal of cardiology.

[29]  L. Guize,et al.  Impaired Fasting Glucose, Blood Pressure and Cardiovascular Disease Mortality , 2002, Hypertension.

[30]  S. Yusuf MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[31]  A. Catapano,et al.  Low density lipoprotein oxidation, antioxidants, and atherosclerosis , 2000, Current opinion in cardiology.

[32]  G. Davı̀,et al.  Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.

[33]  J. Yoshikawa,et al.  Oxidative Stress in Leukocytes Is a Possible Link Between Blood Pressure, Blood Glucose, and C-Reacting Protein , 2002, Hypertension.